{
    "clinical_study": {
        "@rank": "77336", 
        "arm_group": [
            {
                "arm_group_label": "MEDI1814 IV", 
                "arm_group_type": "Experimental", 
                "description": "Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg."
            }, 
            {
                "arm_group_label": "IV Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg."
            }, 
            {
                "arm_group_label": "MEDI1814 Sub Cutaneous Injection", 
                "arm_group_type": "Experimental", 
                "description": "2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort"
            }, 
            {
                "arm_group_label": "Subcutaneous Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety, drug levels and effects on the body of 1\n      or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer's Disease or healthy\n      elderly people."
        }, 
        "brief_title": "SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Mild-Moderate Alzheimer's Disease", 
            "Healthy Elderly"
        ], 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria Male and female (non child bearing potential) subjects Mild-moderate\n        Alzheimer's Disease\n\n        Exclusion Criteria History or evidence of significant autoimmune disease Presence of\n        psychiatric disorder which would affect completion of the study Current serious or\n        unstable clinically important illness"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "242", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02036645", 
            "org_study_id": "D4750C00001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MEDI1814 IV", 
                    "IV Placebo"
                ], 
                "description": "Monoclonal antibody for IV Injection", 
                "intervention_name": "MEDI1814 for IV injection", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "MEDI1814 Sub Cutaneous Injection", 
                "description": "Monoclonal antibody for subcutaneous injection", 
                "intervention_name": "MEDI1814 for Subcutaneous Injection", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "IV Placebo", 
                "description": "Placebo for IV injection", 
                "intervention_name": "IV Placebo", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Subcutaneous Placebo", 
                "description": "Subcutaneous Placebo Injection", 
                "intervention_name": "Placebo for Subcutaneous Injection", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Glendale", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hallandale Beach", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease.", 
        "other_outcome": {
            "description": "Samples will be taken to assess ApoE genotype, central and peripheral protein biomarkers. A novel cognitive assessment scale, the MCI screen, will be assessed for utility in future studies", 
            "measure": "To Assess Exploratory Measures of ApoE genotype, central and peripheral protein biomarkers and MCI screen", 
            "safety_issue": "No", 
            "time_frame": "Basline up to 113 days post single dose/169 days post mutiple dose"
        }, 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Robert C Alexander, MD"
        }, 
        "overall_official": [
            {
                "affiliation": "AstraZeneca", 
                "last_name": "Robert C Alexander, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Glendale Parexel Early Phase Clinical Unit", 
                "last_name": "David Han, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Vital signs, ECG, clinical laboratory testing, MRI, Columbia Suicide Severity Rating Scale", 
            "measure": "To Assess Safety & Tolerability of MEDI1814 by a panel of adverse event measures: Physical exam, Vital signs, ECG, clinical laboratory testing, MRI, Columbia Suicide Severity Rating Scale", 
            "safety_issue": "Yes", 
            "time_frame": "All visits from screening up to 113 days post single dose/169 days post multiple dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02036645"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "\ufeffBlood samples will be taken for assessments. Single Ascending Dose: Cmax, Cmin, tmax, AUC, t1/2, CL and Vz. Mutiple Ascending Dose First dose: Cmax, Cmin, tmax, AUC, and for Third Dose: Cmax, Cmin, tmax, AUC, t1/2, CL, Vz, Vss and accumulation ratios", 
                "measure": "To Assess Pharmacokinetics of MEDI1814 in terms of: \ufeffCmax, Cmin, tmax, AUC, t1/2, CL and Vz for SAD and for MAD First dose: Cmax, Cmin, tmax, AUC and Third Dose: Cmax, Cmin, tmax, AUC, t1/2, CL, Vz, Vss and accumulation rations", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 113 days post single dose/169 days post multiple dose"
            }, 
            {
                "description": "Blood and CSF samples will be taken for assessment. Blood biomarkers: total amyloid beta 1-42 and CSF biomarkers: total and free amyloid beta 1-42; total amyloid beta 1-40", 
                "measure": "To Assess Pharmacodynamics of MEDI1814 in terms of a) blood biomarkers: total amyloid beta 1-42 and b) CSF biomarkers: total and free amyloid beta 1-42 and total amyloid beta 1-40", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 113 days post single dose/169 days post multiple dose"
            }, 
            {
                "description": "Blood samples will be taken for assessment of screening results and anti drug antibody (ADA) titre post dosing", 
                "measure": "To Assess Immunogenicity of MED1814 in terms of anti drug antibody detection", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to 113 days post dose for single dose/169 days post multiple dose"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}